About: Lineage B.1.1.7 with E484K

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Lineage B.1.1.7 with E484K Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

Attributes	Values
rdf:type	Item
owl:sameAs	Lineage B.1.1.7 with E484K
rdfs:label	Lineage B.1.1.7 with E484K (en) Lineage B.1.1.7 with E484K (nb) 带E484K的B.1.1.7谱系 (zh)
skos:prefLabel	Lineage B.1.1.7 with E484K (en) Lineage B.1.1.7 with E484K (nb) 带E484K的B.1.1.7谱系 (zh)
name	Lineage B.1.1.7 with E484K (en) Lineage B.1.1.7 with E484K (nb) 带E484K的B.1.1.7谱系 (zh)
instance of	wds:Q106171244-15322685-41f3-b4a1-fe62-7f5f3ee4b8e7 wds:Q106171244-225a31fc-4016-4474-fecd-ecc861b338c0 wds:Q106171244-476cdc67-410c-c5a0-6636-ee1cca3a73d3
part of	wds:Q106171244-a6bc98f7-472b-4413-c725-cf2cd244ce5b
instance of	variant of concern variant of SARS-CoV-2 group or class of strains
part of	SARS-CoV-2 Alpha variant
subclass of	wds:Q106171244-0bdb26c8-4c97-f3b6-7398-e25aa49b9315
subclass of	SARS-CoV-2 Alpha variant
Google Knowledge Graph ID	wds:Q106171244-CD0565FD-7DF2-408F-9BB0-1E6B60FE03DA
Google Knowledge Graph ID	http://g.co/kg/g/11r3_6jcgg
Google Knowledge Graph ID	/g/11r3_6jcgg
skos:altLabel	B.1.1.7 (en) VOC-202102/02 (en) VOC-21FEB-02 (en) Variant of Concern 202102/02 (en) Variant of Concern 21FEB-02 (en)
is about of	Lineage B.1.1.7 with E484K https://www.wikidata.org/wiki/Special:EntityData/Q106171244 Variant of Concern 202102/02 https://no.wikipedia.org/wiki/Lineage_B.1.1.7_with_E484K
is has part(s) of	SARS-CoV-2 Alpha variant
is main subject of	Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 Dynamics of SARS-CoV-2 Alpha (B.1.1.7) variant spread: The wastewater surveillance approach Real-Time RT-PCR Allelic Discrimination Assay for Detection of N501Y Mutation in the Spike Protein of SARS-CoV-2 Associated with B.1.1.7 Variant of Concern The Natural Stilbenoid (-)-Hopeaphenol Inhibits Cellular Entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7, and B.1.351 Variants Importation of SARS‐CoV‐2 Variant B.1.1.7 in Pakistan Isolation and characterization of the new SARS-CoV-2 variant in travellers from the United Kingdom to India: VUI-202012/01 of the B.1.1.7 lineage Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-January 12, 2021 Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera Surveillance of SARS-CoV-2 lineage B.1.1.7 in Slovakia using a novel, multiplexed RT-qPCR assay In Vitro Rapid Antigen Test Performance with the SARS-CoV-2 Variants of Concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta) Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States Rapid Increase of SARS-CoV-2 Variant B.1.1.7 Detected in Sewage Samples from England between October 2020 and January 2021 TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351) SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies Altered Subgenomic RNA Expression in SARS-CoV-2 B.1.1.7 Infections Characterisation of B.1.1.7 and Pangolin coronavirus spike provides insights on the evolutionary trajectory of SARS-CoV-2 ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7 Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques Low dose inocula of SARS-CoV-2 B.1.1.7 variant initiate more robust infections in the upper respiratory tract of hamsters than earlier D614G variants The high infectivity of SARS-CoV-2 B.1.1.7 is associated with increased interaction force between Spike-ACE2 caused by the viral N501Y mutation Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study Functional evaluation of the P681H mutation on the proteolytic activation of the SARS-CoV-2 variant B.1.1.7 (Alpha) spike SARS-CoV-2 variant B.1.1.7 caused HLA-A2<sup>+</sup> CD8<sup>+</sup> T cell epitope mutations for impaired cellular immune response B.1.1.7 and B.1.351 variants are highly virulent in K18-ACE2 transgenic mice and show different pathogenic patterns from early SARS-CoV-2 strains Increased transmissibility of SARS-CoV-2 lineage B.1.1.7 by age and viral load In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies Immunoinformatic analysis of structural and epitope variations in the spike and Orf8 proteins of SARS-CoV-2/B.1.1.7 The P681H mutation in the Spike glycoprotein confers Type I interferon resistance in the SARS-CoV-2 alpha (B.1.1.7) variant Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants by Two Potent SARS-CoV-2 Neutralizing Antibodies Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021 Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera Tracking of SARS-CoV-2 Alpha variant (B.1.1.7) in Palestine Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7 Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2 The Alpha Variant (B.1.1.7) of SARS-CoV-2 Failed to Become Dominant in Mexico Rapid and High-Throughput Reverse Transcriptase Quantitative PCR (RT-qPCR) Assay for Identification and Differentiation between SARS-CoV-2 Variants B.1.1.7 and B.1.351 Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil) and Delta (B.1.617.2, India) Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study Tracking SARS-CoV-2 lineage B.1.1.7 dissemination: insights from nationwide spike gene target failure (SGTF) and spike gene late detection (SGTL) data, Portugal, week 49 2020 to week 3 2021 Descriptive comparison of admission characteristics between pandemic waves and multivariable analysis of the association of the Alpha variant (B.1.1.7 lineage) of SARS-CoV-2 with disease severity in inner London Mutations in the B.1.1.7 SARS-CoV-2 Spike Protein Reduce Receptor-Binding Affinity and Induce a Flexible Link to the Fusion Peptide Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 -May 2021 SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7. Structural modelling of SARS-CoV-2 alpha variant (B.1.1.7) suggests enhanced furin binding and infectivity SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States Structural Consequences of Variation in SARS-CoV-2 B.1.1.7. Evolutionary history and introduction of SARS-CoV-2 Alpha VOC/B.1.1.7 in Pakistan through international travelers
is has part(s) of	wds:Q104376647-d244f6b1-47f2-18c0-9725-6854ab8fbfe1
is main subject of	wds:Q109649520-FB627576-D487-4CD0-B0A1-B25F0D38675C

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 177 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software